Rayaldee FDA Approval History
FDA Approved: Yes (First approved June 17, 2016)
Brand name: Rayaldee
Generic name: calcifediol
Dosage form: Extended Release Capsules
Company: OPKO Health, Inc.
Treatment for: Secondary Hyperparathyroidism
Rayaldee (calcifediol) is a vitamin D3 analog indicated for the treatment of secondary hyperparathyroidism associated with vitamin D Insufficiency in stage 3-4 chronic kidney disease.
Development Timeline for Rayaldee
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.